​

Protagonist Therapeutics Ownership | Who Owns Protagonist Therapeutics?

OverviewForecastRevenueFinancialsChart

Protagonist Therapeutics Ownership Summary

Protagonist Therapeutics is owned by 25.03% institutional investors, 1.14% insiders, and 73.83% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 16.00% of PTGX shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 5.94% of its assets in Protagonist Therapeutics shares.

PTGX Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockProtagonist Therapeutics25.03%1.14%73.83%
SectorHealthcare Stocks 279.15%10.63%-189.78%
IndustryBiotech Stocks 63.94%10.67%25.38%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de9.88M16.00%$381.55M
Farallon capital management5.93M9.60%$228.90M
Blackrock5.76M9.39%$199.52M
Rtw investments, lp5.72M9.08%$276.59M
Vanguard group4.22M6.83%$162.89M
Deep track capital, lp3.00M4.76%$145.08M
Bvf inc/il2.58M4.09%$124.53M
Johnson & johnson2.45M3.97%$94.54M
State street2.08M3.40%$72.15M
Jefferies financial group1.49M2.41%$57.49M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Johnson & johnson2.45M24.48%$94.54M
Lynx1 capital management lp733.01K12.69%$35.45M
Adar1 capital management939.67K8.44%$45.44M
Aquilo capital management81.69K7.08%$3.95M
Bvf inc/il2.58M5.08%$124.53M
Deep track capital, lp3.00M4.70%$145.08M
Checkpoint capital175.18K4.65%$8.47M
Rtw investments, lp5.72M4.23%$276.59M
Artia global partners lp333.85K4.09%$16.15M
Eversept partners, lp547.12K2.69%$26.46M

Top Buyers

HolderShares% AssetsChange
Deep track capital, lp3.00M4.70%2.00M
Wellington management group llp940.08K0.01%910.00K
Lynx1 capital management lp733.01K12.69%733.01K
Bvf inc/il2.58M5.08%675.00K
Eagle asset management357.63K0.07%357.63K

Top Sellers

HolderShares% AssetsChange
Pacer advisors---1.88M
Morgan stanley345.29K0.00%-1.53M
Adage capital partners gp---1.20M
State street2.08M0.00%-1.19M
Fairmount funds management---931.89K

New Positions

HolderShares% AssetsChangeValue
Lynx1 capital management lp733.01K12.69%733.01K$35.45M
Eagle asset management357.63K0.07%357.63K$12.59M
Toronto dominion bank340.97K0.02%340.97K$13.16M
Raymond james financial303.31K0.00%303.31K$11.71M
Millennium management134.27K0.00%134.27K$6.49M

Sold Out

HolderChange
Ifp advisors-5.00
Mendota financial group-6.00
Federated hermes-7.00
Nelson, van denburg & campbell wealth management group-11.00
Financial gravity asset management-18.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202519-92.31%15,761,655-75.08%250.24%12-91.18%5-93.33%
Dec 31, 2024147-40.49%31,832,545-48.43%510.52%84-45.81%42-35.38%
Sep 30, 202424627.46%61,406,0774.02%991.07%15469.23%65-7.14%
Jun 30, 20241932.66%59,030,802-1.50%960.99%91-17.27%7027.27%
Mar 31, 202418818.24%59,929,9384.29%981.09%11054.93%55-9.84%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
iShares Core S&P Small-Cap ETF3.68M5.94%-10.34K
Vanguard Total Stock Mkt Idx Inv1.97M3.18%1.64K
Vanguard US Total Market Shares ETF1.87M3.05%129.62K
Pacer US Small Cap Cash Cows 100 ETF1.61M2.63%-11.71K
iShares Russell 2000 ETF1.45M2.35%10.09K
SPDR® S&P Biotech ETF983.30K1.59%-16.07K
Vanguard Institutional Extnd Mkt Idx Tr926.59K1.50%6.48K
UBS: US Equity Small Cap Growth744.87K1.25%-
T. Rowe Price Health Sciences685.46K1.11%-86.97K
Fidelity Small Cap Index601.24K0.97%7.60K

Recent Insider Transactions

DateNameRoleActivityValue
Jul 23, 2025PATEL DINESH V PH D President and CEOSell$959.92K
Jul 21, 2025PATEL DINESH V PH D President and CEOSell$705.44K
Jul 22, 2025PATEL DINESH V PH D President and CEOSell$1.21M
Jun 10, 2025MOLINA ARTURO MD Chief Medical OfficerSell$570.30K
Jun 09, 2025MOLINA ARTURO MD Chief Medical OfficerSell$555.10K

Insider Transactions Trends

DateBuySell
2025 Q3-3
2025 Q2-3
2025 Q1-8
2024 Q4-8
2024 Q3-4

PTGX Ownership FAQ

Who Owns Protagonist Therapeutics?

Protagonist Therapeutics shareholders are primarily institutional investors at 25.03%, followed by 1.14% insiders and 73.83% retail investors. The average institutional ownership in Protagonist Therapeutics's industry, Biotech Stocks , is 63.94%, which Protagonist Therapeutics falls below.

Who owns the most shares of Protagonist Therapeutics?

Protagonist Therapeutics’s largest shareholders are Blackrock funding, inc. /de (9.88M shares, 16.00%), Farallon capital management (5.93M shares, 9.60%), and Blackrock (5.76M shares, 9.39%). Together, they hold 35.00% of Protagonist Therapeutics’s total shares outstanding.

Does Blackrock own Protagonist Therapeutics?

Yes, BlackRock owns 9.39% of Protagonist Therapeutics, totaling 5.76M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 199.52M$. In the last quarter, BlackRock increased its holdings by 188.63K shares, a 3.39% change.

Who is Protagonist Therapeutics’s biggest shareholder by percentage of total assets invested?

Johnson & johnson is Protagonist Therapeutics’s biggest shareholder by percentage of total assets invested, with 24.48% of its assets in 2.45M Protagonist Therapeutics shares, valued at 94.54M$.

Who is the top mutual fund holder of Protagonist Therapeutics shares?

iShares Core S&P Small-Cap ETF is the top mutual fund holder of Protagonist Therapeutics shares, with 5.94% of its total shares outstanding invested in 3.68M Protagonist Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools